Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.315
-0.024 (-7.08%)
At close: Feb 21, 2025, 4:00 PM
0.304
-0.011 (-3.37%)
After-hours: Feb 21, 2025, 7:39 PM EST
Eterna Therapeutics Market Cap
Eterna Therapeutics has a market cap or net worth of $16.18 million as of February 21, 2025. Its market cap has increased by 92.59% in one year.
Market Cap
16.18M
Enterprise Value
49.61M
1-Year Change
92.59%
Ranking
Category
Stock Price
$0.31
Market Cap Chart
Since December 1, 1998, Eterna Therapeutics's market cap has decreased from $21.10M to $16.18M, a decrease of -23.33%. That is a compound annual growth rate of -1.01%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 21, 2025 | 16.20M | 7.28% |
| Dec 31, 2024 | 15.10M | 55.67% |
| Dec 29, 2023 | 9.70M | 2.11% |
| Dec 30, 2022 | 9.50M | -95.62% |
| Dec 31, 2021 | 217.00M | 3,187.88% |
| Dec 31, 2020 | 6.60M | 3.13% |
| Dec 31, 2019 | 6.40M | 14.29% |
| Dec 31, 2018 | 5.60M | -47.17% |
| Dec 29, 2017 | 10.60M | -44.79% |
| Dec 30, 2016 | 19.20M | 29.73% |
| Dec 31, 2015 | 14.80M | -63.55% |
| Dec 31, 2014 | 40.60M | -10.18% |
| Dec 31, 2013 | 45.20M | 203.36% |
| Dec 31, 2012 | 14.90M | -1.97% |
| Dec 30, 2011 | 15.20M | -34.20% |
| Dec 31, 2010 | 23.10M | -15.07% |
| Dec 31, 2009 | 27.20M | 262.67% |
| Dec 31, 2008 | 7.50M | -78.07% |
| Dec 31, 2007 | 34.20M | -54.22% |
| Dec 29, 2006 | 74.70M | -6.74% |
| Dec 30, 2005 | 80.10M | -52.55% |
| Dec 31, 2004 | 168.80M | -3.87% |
| Dec 31, 2003 | 175.60M | 272.03% |
| Dec 31, 2002 | 47.20M | 42.17% |
| Dec 31, 2001 | 33.20M | 52.29% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 782.80B |
| UnitedHealth Group | 461.55B |
| Johnson & Johnson | 384.04B |
| Novo Nordisk | 370.06B |
| AbbVie | 353.97B |
| Abbott Laboratories | 230.52B |
| AstraZeneca | 227.07B |
| Merck & Co. | 221.18B |